|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||33.69 - 36.84|
|52 Week Range||8.55 - 40.01|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 03, 2021 - Mar 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.50|
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 165,300 shares of the Company’s common stock at an exercise price per share of $38.19, which was the closing price on January 25, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).